FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug Administration U.S. Food and Drug Administration Center for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 
 

Warning Letters and Untitled Letters
to Pharmaceutical Companies
2008

These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office. This page only covers Division of Drug Marketing and Communications and Headquarters Warning Letters.  For District Office Warning Letters see the Main FDA FOI Warning Letters Page.    Some of the letters have been redacted or edited to remove confidential information. Click on the month to view the letters in Adobe Acrobat format. [more...]

2008 [2007] [2006] [2005] [2004] [2003] [2002] [2001] [2000] [1999] [1998] [1997]
August 2008
Product/Issue Company/Individual Division Released Posted

Bystolic (nebivolol) Tablets (Warning Letter)

Forest Laboratories, Inc. Division of Drug Marketing, Advertising, and Communications 8/28/2008 9/8/2008

Inspection (Warning Letter)

Hospital Municipal de San Juan IRB Division of Scientific Investigations 8/15/2008 8/20/2008
June 2008
Product/Issue Company/Individual Division Released Posted

Clinical Investigation (Warning Letter)

Nagarjuna R. Ponugoti, M.D. Division of Scientific Investigations 6/6/2008 7/9/2008

Clinical Investigation (Warning Letter)

Travanti Pharma, Inc. Division of Scientific Investigations 6/30/2008 7/2/2008
May 2008
Product/Issue Company/Individual Division Released Posted
Clinical Investigation (Warning Letter) Arturo Corces, M.D. Division of Scientific Investigations 5/28/2008 7/9/2008
Clinical Investigation (Warning Letter) Willa A. Hsueh, M.D. Division of Scientific Investigations 5/30/2008 7/9/2008
Clinical Investigation (Warning Letter) Edward Mostel, M.D.. Division of Scientific Investigations 5/16/2008 7/9/2008

Fosrenol

Shire Development, Inc. Division of Drug Marketing, Advertising, and Communications 5/1/2008 5/8/2008

Trileptal (Warning Letter)

Novartis Pharmaceuticals Corporation Division of Drug Marketing, Advertising, and Communications 5/1/2008 5/8/2008
April 2008
Product/Issue Company/Individual Division Released Posted
Inspection (Warning Letter) Changzhou SPL Company, Ltd. Division of Manufacturing and Product Quality 4/21/2008 4/21/2008

Peridex (Warning Letter)

Zila Pharmaceuticals, Inc. Division of Drug Marketing, Advertising, and Communications 4/18/2008 4/22/2008
Viagra (Warning Letter) Pfizer, Inc. Division of Drug Marketing, Advertising, and Communications 4/16/2008 4/21/2008
March 2008
Product/Issue Company/Individual Division Released Posted

Avinza (Warning Letter)

King Pharmaceuticals, Inc. Division of Drug Marketing, Advertising, and Communications 3/24/2008 3/26/2008
Clinical Investigation (Warning Letter) Saroj Brar, M.D. Division of Scientific Investigations 3/20/2008 4/22/2008
Clinical Investigation (Warning Letter) Ashok Shah, M.D. Division of Scientific Investigations 3/19/2008 4/22/2008
Clinical Investigation (Warning Letter) Frank Whittier, M.D. Division of Scientific Investigations 3/6/2008 4/22/2008
Inspection (Warning Letter) Coast Institutional Review Board Division or Scientific Investigations 3/11/2008 3/26/2008
February 2008
Product/Issue Company/Individual Division Released Posted
BMIS Inspection (Warning Letter) Kevin W. Klein, M.D. Division or Scientific Investigations 2/13/2008 2/28/2008
Clinical Investigation (Warning Letter) Nasim Golzar, MD Division of Scientific Investigations 2/13/2008 5/15/2008
Inspection (Warning Letter) West Jefferson Medical Center IRB Division of Scientific Investigations 2/25/2008 4/1/2008
January 2008
Product/Issue Company/Individual Division Released Posted
BMIS Inspection (Warning Letter) Replidyne, Inc. Division or Scientific Investigations 1/18/2008 2/15/2008
Inspection (Warning Letter) Tomita Pharmaceutical Co., Ltd Division of Manufacturing and Product Quality 1/14/2008 1/23/2008

Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter.  If you wish to obtain available additional information on the current status of an issue in a particular warning letter or notice of violation on this website, please contact the Agency or the recipient of the letter directly.  Inquiries to FDA should be sent to:

Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane, Rockville, MD 20857

Instructions for how to submit an FOI request can be found on the FDA FOI Page.

The letters are arranged in chronological order by month.  Click on the product name to view the letters in Adobe Acrobat (PDF) format. Go here for further information about Adobe Acrobat and download instructions.

Also see the "Cyber" Letters.

top arrow Back to Top     back arrow Index

Date created: February 28, 2008; updated September 8, 2008

horizonal rule